Stock Analysis, Dividends, Split History

WHLR / Wheeler Real Estate Investment Trust, Inc. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Price4.25
Volume28,400.00
Market Cap ($M)41.47
Enterprise Value ($M)40.62
Book Value ($M)59.45
Book Value / Share6.34
Price / Book0.70
NCAV / Sharen/a
Price / NCAVn/a
Share Statistics
Common Stock Shares Outstanding 8,744,189
Preferred Stock Shares Outstanding 562
Common Shares Outstanding 8,946,399
Scoring Models
Piotroski F-Score4.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)-0.20
Return on Assets (ROA)-0.03
Return on Equity (ROE)-0.13
Balance Sheet (mrq) ($M)
Assets535.79
Liabilities398.44
Quick Ration/a
Current Ration/a
Income Statement (mra) ($M)
Revenues58,535,000.00
Other Sales Revenue Net1,521,000.00
Disposal Group Including Discontinued Operation Revenue0.00
Property Management Fee Revenue927,000.00
Operating Income0.54
Net Income-12.78
Earnings Per Share Basic And Diluted-2.54
Cash Flow Statement (mra) ($M)
Cash From Operations24.76
Cash from Investing-2.98
Cash from Financing-2.98
Identifiers and Descriptors
CUSIP963025101
Central Index Key (CIK)1527541
Related CUSIPS
963025705

Split History

Stock splits are used by Wheeler Real Estate Investment Trust, Inc. to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

17h - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

17h - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

19h - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

Related News Stories

How To Retire In 2018 In A Bull Market Without Going To Cash

2018-08-29 seekingalpha
Retiring in the market today can be scary, but we will go over how to avoid the landmines. (23-0)

Wheeler Real Estate Investment Trust (WHLR) CEO Dave Kelly on Q2 2018 Results - Earnings Call Transcript

2018-08-09 seekingalpha
Wheeler Real Estate Investment Trust (NASDAQ:WHLR) Q2 2018 Results Earnings Conference Call August 8, 2018 11:00 AM ET (14-0)

Plymouth Industrial REIT: If Institutions Will Not Buy Your Stock, Find A Retail Investor

2018-07-30 seekingalpha
June's run-up in price after the offering was pulled was likely due to shorts covering their position. (1-0)

The State Of REITs: May 2018 Edition

2018-05-11 seekingalpha
The REIT rally that began in March grew stronger in April as REITs again outperformed the broader market. (11-1)

Wheeler Real Estate Investment's (WHLR) CEO Dave Kelly on Q1 2018 Results - Earnings Call Transcript

2018-05-09 seekingalpha
Wheeler Real Estate Investment Trust (NASDAQ:WHLR) Q1 2018 Earnings Conference Call May 9, 2018 10:00 AM ET (9-0)

CUSIP: 963025101